The FARSB antibody targets the β-subunit of phenylalanyl-tRNA synthetase (PheRS), a key enzyme in the aminoacylation of tRNA with phenylalanine during protein synthesis. PheRS is a heterotetrameric enzyme composed of two α (FARSA) and two β (FARSB) subunits, conserved across eukaryotes. FARSB plays a structural and catalytic role, aiding in tRNA recognition and ensuring fidelity in attaching phenylalanine to its cognate tRNA. Dysregulation of FARSB is linked to mitochondrial disorders, neuropathies, and cancers, with mutations in FARSB associated with Charcot-Marie-Tooth disease (CMT) and pulmonary fibrosis. Antibodies against FARSB are used in research to study its expression, subcellular localization (mitochondrial vs. cytoplasmic isoforms), and molecular interactions. They are critical tools in Western blotting, immunofluorescence, and immunohistochemistry to explore FARSB's role in disease mechanisms or stress responses. Validated antibodies often undergo knockout controls to ensure specificity, given the structural homology among aminoacyl-tRNA synthetases. Research on FARSB also extends to its non-canonical roles in signaling pathways and immune modulation, highlighting its therapeutic and diagnostic potential.